CMTRF is funding an exciting project with 82VS, the Venture Studio of Alloy Therapeutics, to solve one of the toughest problems in Charcot-Marie-Tooth disease; getting RNA-based therapies to the peripheral nerves and cells damaged by CMT. This CMTRF-funded project uses specially designed antibodies to guide RNA therapies directly to nerve cells. If successful, it could open the door to an entirely new class of treatments for CMT1A and lay the groundwork for therapies that help many forms of the disease.

Dr. Carlos Loya will walk through the challenge of delivering treatments to nerves, share early encouraging results from this CMTRF-funded project, and discuss what this approach could mean for the future of CMT care. Join us for this special opportunity to hear directly from the team your generosity is powering — and to see how your support is helping turn cutting-edge science into real progress for people living with CMT.

Date: December 11, 2025
Time: 7:00 p.m. ET
Location: Zoom

There is no cost to attend. To register, click here.

November 6, 2025

July 9, 2024